Pfizer announced third-quarter 2026 revenues of $16.6 billion, matching the prior-year period operationally, while reporting adjusted diluted EPS of $0.87. Driven by solid performance in non-COVID and newly launched products, the company raised its full-year 2026 revenue guidance to a range of $62.0 to $64.0 billion and narrowed its adjusted diluted EPS guidance to $2.95 to $3.05. Shareholders also saw the appointment of Cecile Guegan as Chief Financial Officer and Executive Vice President.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Pfizer's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$62.58B
-1.6%
$1.36
-3.5%
12.4%
FY2024
$63.63B
+25.0%
$1.41
+281.1%
12.6%
FY2023
$50.91B
-44.5%
$0.37
-93.2%
4.2%
FY2022
$91.79B
+24.7%
$5.47
+42.1%
34.2%
FY2021
$73.64B
+76.8%
$3.85
+136.2%
29.8%
Frequently asked questions
When is Pfizer's next earnings date?
Pfizer has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Pfizer earn last quarter?
For the quarter ended Sep 2026, Pfizer reported diluted EPS of $0.56 (-9.7% year over year) on revenue of $16.58B (-0.4%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.